Abstract 104P
Background
Although checkpoint inhibitors have improved first-line treatment for non–small cell lung cancer (NSCLC), a therapeutic need remains for patients whose disease does not respond or who experience disease progression after anti-PD-L1/PD-1 immunotherapy. Cadonilimab (AK104) is a bispecific antibody targeting PD-1 and CTLA-4 simultaneously. Here, we reported the efficacy and safety of cadonilimab with or without single-agent chemotherapy as a second- or later-line setting for metastatic NSCLC who developed disease progression after checkpoint inhibitor and chemotherapy.
Methods
The study population derived from retrospectively analyzed data (08/2022-04/2024) of patients treated with cadonilimab as second- or later-line therapy for metastatic NSCLC at Affiliated Hospital of Guangdong Medical University. Baseline characteristics, treatment patterns, and clinical outcomes, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and treatment-related adverse events (TRAEs) were analyzed.
Results
21 patients were enrolled, of which 11 (52.3%) received cadonilimab as a third or later line therapy. The median age was 66 years old (range: 54-87), 16 (76.2%) were male, 10 (47.6%) had ECOG PS 2 or 3, and 4 (19.0%) had brain metastasis. Among evaluable patients, 5 reached partial response (PR) and 9 were stable disease (SD). The ORR was 29.4% and DCR was 82.4%. The median PFS was 6.77 months (95% confidence interval: 5.28-8.27) and median OS was not mature. Three patients (14.3%) experienced grade≥3 TRAEs. The most common TRAEs (≥10%) included anemia (42.9%), hypoleukocytosis (28.6%), and aspartate aminotransferase increased (19.1%), hypothyroidism(14.3%), alanine aminotransferase increased(14.3%). No treatment-related deaths were reported.
Conclusions
This real-world analysis further confirmed the promising efficacy and safety of cadonilimab as a second- or later-line setting for metastatic NSCLC who developed disease progression after checkpoint inhibitor and chemotherapy. Further exploration is ongoing and the updated analysis in a larger population is expected in the future.
Legal entity responsible for the study
Hualin Chen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
53P - Novel ex-vivo manufacturing of transiently expressed armoured CAR T cells for glioblastoma
Presenter: Saket Srivastava
Session: Poster Display session
Resources:
Abstract
54P - Superior antitumor activities of fourth-generation CAR-T cells containing three costimulatory domains targeting GD2-positive tumors
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
55P - Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment
Presenter: Marta Soria Castellano
Session: Poster Display session
Resources:
Abstract
56P - Potent antitumor efficiency of CD19-CAR T cells self-secreting PD-L1 x CD3 BiTE against aggressive B-cell lymphoma
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
57P - SENDER™ Directed LNP Delivery of mRNA for In Situ generation of highly potent CAR T Cells
Presenter: Biao Ma
Session: Poster Display session
Resources:
Abstract
58P - Cardiovascular outcomes of novel CAR-T cell therapies: A meta-analysis of incidence, risk factors, and management of cardiotoxicity
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract
59P - Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials
Presenter: Nicolas Mach
Session: Poster Display session
Resources:
Abstract
60P - Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
61P - Optimized protocol for the accelerated production of dendritic cell-derived exosomes (DEXs): Achieving speed without compromising efficacy
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
62P - Ecto-CRT induction of NKp46 surface expression increases osimertinib-resistant lung cancer’s sensitivity to NK cells
Presenter: Sumei Chen
Session: Poster Display session
Resources:
Abstract